Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target
Mirvetuximab soravtansine
No preference
No preference

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT04209855IIIPlatinum resistant FRalpha+ high grade serous ovarian cancerMIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha ExpressionAL, AK, AZ, CA, CO, CT, FL, GA, IL, IN, KS, KY, LA, MD, MA, MI, MN, MO, MT, NV, NJ, NY, NC, OH, OK, OR, PA, RI, TN, TX, VA, WA, WVView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Mirvetuximab soravtansineM9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid ConjugateADC: anti-FOLR1 + microtubule destabilizer (DM4)Clinical Trials
NCT03552471IRecurrent FRalpha+ ovarian cancer (in expansion)Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerOHView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Mirvetuximab soravtansineM9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid ConjugateADC: anti-FOLR1 + microtubule destabilizer (DM4)Clinical Trials
RucaparibRubraca, CO-338, PF 01367338, AG-014699PARP inhibitorApproved in Ovarian Cancer

If you have any questions or would like help with your search, please call us at: 858-657-0282 or email us at patientsupport@clearityfoundation.org.